Angel Broking neutral on Dr Reddys Laboratories

Angel Broking has maintained a neutral rating on Dr Reddys Laboratories (DRL) in its February 21, 2013 research report. The research firm expects net sales to report a 9.8% CAGR to Rs 11,662cr and adjusted EPS to record a 2.3% CAGR to Rs 92.9 over FY2012-14E.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Travelcafe
moneycontrol.com

Home » News » Recommendations

Feb 23, 2013, 05.43 PM | Source: Moneycontrol.com

Angel Broking neutral on Dr Reddys Laboratories

Angel Broking has maintained a neutral rating on Dr Reddys Laboratories (DRL) in its February 21, 2013 research report. The research firm expects net sales to report a 9.8% CAGR to Rs 11,662cr and adjusted EPS to record a 2.3% CAGR to Rs 92.9 over FY2012-14E.

Like this story, share it with millions of investors on M3

Angel Broking neutral on Dr Reddys Laboratories

Angel Broking has maintained a neutral rating on Dr Reddys Laboratories (DRL) in its February 21, 2013 research report. The research firm expects net sales to report a 9.8% CAGR to Rs 11,662cr and adjusted EPS to record a 2.3% CAGR to Rs 92.9 over FY2012-14E.

Post Your Comments

Share Cancel

(more)

, Angel Broking |

Angel Broking has maintained a neutral rating on Dr Reddys Laboratories (DRL) in its February 21, 2013 research report. The research firm expects net sales to report a 9.8% CAGR to Rs 11,662cr and adjusted EPS to record a 2.3% CAGR to Rs 92.9 over FY2012-14E.

"DRL reported more or less just-in 3QFY2013 top-line and bottom-line performance. The company's net sales increased by 3.5% yoy (23% adjusted for the base effect). The growth came in on back of 24% yoy (adjusted) in the US and Emerging Markets. On the EBIT margins came in at 15.0% V/s expected 15.8%. Consequently the net profit came in at Rs 363cr, a dip of 29.1%, mostly in line with expectations of Rs 339cr.

DRL reported net sales of Rs 2,865cr for 3QFY2013, registering 23.0% yoy growth, which was a tad lower than our estimate of Rs 2,700cr. The U.S. and Emerging markets grew by 24% yoy (adjusted) were the key growth drivers for the company. The domestic market reported a strong growth of 12.0% yoy. On the positive side the PSAI segment posted a robust growth of 28.0% yoy during the quarter. The company's EBIT margin came in at 15.0% V/s expected 15.8% and contracting by 11.7%, leading to a dip of 29.1% to Rs 363cr during the quarter.

DRL has reinforced its earlier revenue guidance of US$2.7bn by FY2013E with RoCE of 25%. We expect net sales to report a 9.8% CAGR to Rs 11,662cr and adjusted EPS to record a 2.3% CAGR to Rs 92.9 over FY2012-14E. We maintain our neutral on the stock," says Angel Broking research report.

Shares held by Mutual Funds/UTI

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click here

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Angel Broking neutral on Dr Reddys Laboratories

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login